Hemoglobin Interlaken in combination with beta thalassemia trait by Ojeda, Mara Jorgelina et al.
[Thalassemia Reports 2013; 3:e3] [page 11]
Hemoglobin Interlaken in combination with beta thalassemia trait
Mara J. Ojeda,1 Susana M. Perez,1Karina L. Calvo,1 Arianna F. Pratti,1María E. Voss,1 Angela C. Milani,1Gustavo Chiappe,2 Beatriz Erramouspe,2Irma M. Bragós11Cátedra Hematología, Facultad CienciasBioquímicas y Farmacéuticas,Universidad Nacional de Rosario,Rosario, Santa Fe, Argentina; 2Unidad Asistencial Dr. César Milstein,Ciudad Autónoma de Buenos Aires,Argentina
Abstract
We report a rare a1 globin gene variant (Hb
Interlaken) found in a 63-year-old woman of
Italian ancestry living in Buenos Aires
Province, Argentina. The variant, a missense
mutation at cd15 (GGT → GAT) causing a Gly
→ Asp amino acid substitution and also known
as Hb J Oxford, was found in combination with
the common  thalassemia trait cd 39 (C→T).
The clinical picture of the patient was that of a
b-thalassemia trait.
Introduction
In 1964 Liddell first described hemoglobin
Interlaken in an English family.1  Only isolated
reports exist in which the same mutation was
named Hb J-Oxford or Hb N-Cosenza.2  The
variant has thus far been described in combi-
nation with b-thalassemia homozygosity and
HbS but not in combination with b-tha-
lassemia trait and never before in Argentina, a
multi ethnic country with many ethnic compo-
nents.
Hb Interlaken is a stable a1 chain variant
caused by a GAC→CAC transversion at codon
15 of the a1 gene causing a Gly→Asp amino
acid substitution (HGVS nomenclature
HBA1:c.47G>A).3
Case Report
We report the identification of Hb Interlaken
in a 63-year-old Argentinian woman of Italian
ancestry, referred to our laboratory because of
a microcytic hypocromic anemia. Hb
Interlaken was found in this patient in combi-
nation with the common Mediterranean b0 tha-
lassemia trait cd 39 (C→T) (HGVS nomencla-
ture HBB:c.118C>T), the most frequent b- tha-
lassemia mutation in Argentina.4
Complete blood count (CBC) was obtained
with a Coulter Counter model ACT10
(Beckman Coulter Inc, Brea, CA, USA): Hb
(g/L) 11.6, RBC (1012/L) 5.88, MCV (fL) 62.4,
HCM (pg) 19.7, reticulocytes (%) 1.0.
The separation of the Hb fractions was done
on alkaline cellulose acetate electrophoresis
(Figure 1A). The presence of a J like minor
fraction was suggestive for an a chain variant.
Hb A2 measured by elution from electrophore-
sis followed by spectrophotometric measure-
ment of the absorbance at 415 nm was estimat-
ed at 3% while Hb X was 28%. In spite of the
normal HbA2 level, the CBC, the slightly elevat-
ed HbF (1.3%) estimated according to Betke et
al.5,6 indicated a possible b-thalassemia trait
while the very low mean corpuscolar hemoglo-
bin could be an indication for a b-/a tha-
lassemia combination. Iron parameters were
measured as previously described:7 serum
iron 56 ug/dL, total iron-binding capacity 328
ug/dL, transferrin saturation 17% and serum
ferritin 4 ng/mL.8 Isopropanol,9  heat stability
and sickle tests were performed and were all
negative.
DNA was extracted from peripheral blood
sample.10  Amplification refractory mutation
system-polymerase chain reaction (ARMS-
PCR)11 was used to confirm the presence of
the b039 mutation (data not shown).
Alpha thalassemia deletion analysis was
done using Gap-PCR12 taking into account the
ethnic origin and hematological data of the
patient while for point mutation analysis
amplification of the a2- and a1-globin genes
was performed as previously described by
using oligonucleotide primers (CyberSyn,
Lenni, PA, USA); the common forward primers
FAa2: 5’-CGCGCTCGCGGCCCGGCAC-3’, and
reverse specific primers for the a2 gene: 5’-
GGGAGGCCCATCGGGCAGGAGGAAC-3’ and a1
gene: 5’-GGGGGGAGGCCCAAGGGGCAAGAA-3’.
Sequencing was done using a Big Dye
Terminators Ready Reaction Kit (Perkin-Elmer
Cetus, Norwalk, CT, USA) in an ABI PRISM 310
sequencer (Perkin-Elmer Cetus). Primers
used for sequencing the two genes were the
following: exon 1, common forward primers
FAa2; exon 2, primer S2 (5’-CCCGCCCGGACC-
CACA-3’); exon 3, primer S3 (5’-
GCGGGTTGCGGGAGGT-3’). The reverse specif-
ic primers for the a1 gene were used to con-
firm the mutation. 
GAP-PCR were used to detect a0 deletions -
(a)20.5, —MED and a+ deletions -a3.7 and -
a4.2 and were all negative. Sequencing of a1
gene revealed a GAC → CAC (Asp→ His) sub-
stitution at codon 15, corresponding to Hb
Interlaken (Figure 1B).
Even though Hb Interlaken is detectable by
electrophoresis a correct characterization of
the genotype requires better methods, espe-
cially in combination with  and a thalassemia.
Then more sophisticated systems able to
measure Hb fractions more precisely like high-
performance liquid chromatography or capil-
lary electrophoresis13 are needed before molec-
ular analysis.
In our case the estimation of the HbA2 that
should have been elevated was typically normal
risking misdiagnosis. The underestimation
was due to the fact that part of the delta chain
is bound by the mutated a chain and this
abnormal HbA2 fraction migrates on a different
spot and is lost for measurement. Therefore
the measured HbA2 value (3%) should be aug-
mented by 28% resulting into a 3.84% a still
ambiguous but elevated HbA2.6 Even though
our value (28%) for hemoglobin variant J-
Oxford is high, the consulted references
showed values between 21 and 25%.14-16
It is the first time that this abnormal hemo-
globin is described in our country. The low red
blood cell indexes observed in this case are
due to co-inheritance of b0 thalassemia and
the underestimation of HbA2 could be caused
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by iron deficiency in the patient at the time of
diagnosis and lost of the abnormal HbA2 frac-
tion.  
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Case Report
Figure 1. A) Hemoglobin electrophoresis at alkaline pH. B) Sequencing of the a1-globin
gene showed one mutation corresponding to Hb Interlaken (Hb J-Oxford, Hb N-
Cosenza), [a15Gly → Asp, GGT>GAT].
No
n-c
om
me
rci
al 
us
e o
nly
